Cboe UK CHF

Alcon Inc. (ALCZ.XC)

79.94

+0.34

+(0.43%)

At close: May 9 at 4:19:56 PM GMT+1

Alcon Announces Results of 2025 Annual General Meeting

GENEVA, May 06, 2025--Alcon Announces Results of 2025 Annual General Meeting

Business Wire 4 days ago

ALC
Do Options Traders Know Something About Alcon Stock We Don't?

Investors need to pay close attention to ALC stock based on the movements in the options market lately.

Zacks 10 days ago

ALC.SW
Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS

GENEVA, April 25, 2025--Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS

Business Wire 16 days ago

ALC
Here’s Why ClearBridge Large Cap Growth Strategy Sold Alcon (ALC)

ClearBridge Investments, an investment management company, released its “ClearBridge Large Cap Growth Strategy” first quarter 2025 investor letter. A copy of the letter can be downloaded here. The majority of growth indexes entered correction territory during the quarter, due to pressure from the chaotic tariff implementation, concerns about a weakening U.S. economy, and increased inflation. […]

Insider Monkey last month

ALC.SW
Alcon Publishes Agenda for 2025 Annual General Meeting

GENEVA, April 04, 2025--Alcon Publishes Agenda for 2025 Annual General Meeting

Business Wire last month

ALC
ALC Stock May Rise With the Introduction of PanOptix Pro in US

Alcon introduces Clareon PanOptix Pro IOL to select practices across the United States, with commercial availability expected in May.

Zacks last month

ALC.SW

BSX

CAH
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter

GENEVA, April 02, 2025--Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter

Business Wire last month

ALC
The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals

Alcon, Glaukos and Regeneron Pharmaceuticals are part of the Zacks top Analyst Blog.

Zacks last month

REGN

ALC.SW

GKOS
Alcon (ALC) Soars 6.0%: Is Further Upside Left in the Stock?

Alcon (ALC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks last month

NVRO

ALC.SW
Alcon buys majority stake in IPO-seeking cell therapy startup Aurion

The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over the direction of the company, which filed to go public in January.

BioPharma Dive last month

ALC.SW
Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease

GENEVA, March 26, 2025--Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease

Business Wire last month

ALC
Alcon Stock Sees RS Rating Climb To 74

A Relative Strength Rating upgrade for Alcon shows improving technical performance. Will it continue?

Investor's Business Daily last month

ALC

PDEX

PEN
Alcon signs merger agreement to acquire Lensar

The acquisition will include Lensar’s ALLY Robotic Cataract Laser Treatment System and Streamline software technology.

Medical Device Network last month

ALC.SW
Morning Movers: 23andMe plummets after Chapter 11 proceedings and CEO exit

Stock index futures are experiencing a notable surge, reflecting renewed investor optimism, primarily driven by reports suggesting that the U.S. administration may reduce the scope of proposed tariffs, potentially excluding certain sectors. Such developments have bolstered market sentiment, leading to premarket gains across major indices. In the commodities market, oil prices have experienced a slight decline as investors closely monitor ongoing ceasefire talks between Russia and Ukraine. The

TipRanks last month

ALC

PENG

OKLO
Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval

ALC secures CE Mark for Clareon Vivity IOL, bringing advanced presbyopia-correcting lens technology to Europe, enhancing visual outcomes with cutting-edge innovation.

Zacks last month

ALC.SW

BSX

CAH
ALC Stock Rises Following the Merger Agreement With LENSAR

Alcon enters into a definitive merger agreement to acquire LENSAR's ALLY Robotic Cataract Laser Treatment System, proprietary Streamline software technology and LENSAR legacy laser system.

Zacks last month

ALC.SW

MASI

BSX
Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities

GENEVA, March 25, 2025--Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities

Business Wire last month

ALC
Alcon Agrees to Acquire LENSAR, Inc.

GENEVA, Switzerland & ORLANDO, Fla., March 24, 2025--Alcon Agrees to Acquire LENSAR, Inc.

Business Wire last month

ALC
Alcon to Host 2025 Capital Markets Day

GENEVA, March 13, 2025--Alcon to Host 2025 Capital Markets Day

Business Wire last month

ALC
Is it the Right Time to Hold Alcon Stock in Your Portfolio Now?

ALC stays on investors' radar due to its Surgical arm performance and contributions from new products.

Zacks last month

ALC.SW

BSX

Performance Overview

Return	ALCZ.XC	MSCI WORLD (^990100-USD-STRD)
YTD	+4.14%	-0.19%
1-Year	+9.80%	+9.31%
3-Year	+33.94%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Alcon Inc. (ALCZ.XC)

Alcon Announces Results of 2025 Annual General Meeting

Do Options Traders Know Something About Alcon Stock We Don't?

Alcon Elevates Vitreoretinal and Cataract Surgery for Superior Efficiency* with UNITY VCS and UNITY CS

Here’s Why ClearBridge Large Cap Growth Strategy Sold Alcon (ALC)

Alcon Publishes Agenda for 2025 Annual General Meeting

ALC Stock May Rise With the Introduction of PanOptix Pro in US

Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter

The Zacks Analyst Blog Highlights Alcon, Glaukos and Regeneron Pharmaceuticals

Alcon (ALC) Soars 6.0%: Is Further Upside Left in the Stock?

Alcon buys majority stake in IPO-seeking cell therapy startup Aurion

Alcon Acquires Majority Interest in Aurion Biotech, Inc. to Advance Innovative Cell Therapy for Corneal Endothelial Disease

Alcon Stock Sees RS Rating Climb To 74

Alcon signs merger agreement to acquire Lensar

Morning Movers: 23andMe plummets after Chapter 11 proceedings and CEO exit

Alcon Stock Might Rise as Clareon Vivity IOL Secures CE Mark Approval

ALC Stock Rises Following the Merger Agreement With LENSAR

Alcon Announces CE Mark Approval and Commercialization of Clareon Vivity IOL in Europe, Expanding Visual Possibilities

Alcon Agrees to Acquire LENSAR, Inc.

Alcon to Host 2025 Capital Markets Day

Is it the Right Time to Hold Alcon Stock in Your Portfolio Now?

Performance Overview